EMA Recommends Extension of Indications for Inotuzumab Ozogamicin By Ogkologos - April 29, 2026 56 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of paediatric patients with CD22-positive B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Study Examines Whether Blood Test Can Identify Early Cancers June 2, 2020 First Prospective Description of Familial EGFR-mutated Lung Cancer August 23, 2023 FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour April 4, 2025 Your NCI: Top Priorities from AACR 2026 May 4, 2026 Load more HOT NEWS New on NCI’s Websites for June 2020 No OS Benefit for Active Maintenance Treatment with Olaparib Relative to... FDA Approves Sacituzumab Govitecan-hziy for HR-positive Advanced Breast Cancer Individualised Nutritional Support Reduce the Risk of Mortality in Cancer Patients...
